Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors, with phase 2 data published in the New England Journal of Medicine (2023) showing substantial weight reduction
Dosage and Administration: Determining optimal dosages and administration routes for a combined regimen is complex and would require expert guidance
Peptides with fewer residues are more susceptible to rapid enzymatic degradation, leading to shorter systemic exposure. Fosgerau & Hoffmann, Drug Discovery Today Half-Life Each peptide has a defined biological half-life the time it takes for half of the substance to be eliminated from the bloodstream
This makes it especially useful after skin treatments (like micro-needling, laser, microdermabrasion, or peels) or when dealing with flare-ups from rosacea or dermatitis
Oral formulations are mainly discussed for gastrointestinal applications, but research remains limited